Point72 Asset Management
SPRO icon

Point72 Asset Management’s Spero Therapeutics SPRO Stock Holding History

Point72 Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Buy
59,668
+16,089
+37% +$38.2K ﹤0.01% 3577
2025
Q4 		$102K Buy
+43,579
New +$101K ﹤0.01% 3739
2018
Q4 		– Sell
-44,000
Closed -$462K – 1185
2018
Q3 		$462K Buy
+44,000
New +$511K ﹤0.01% 932

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management's SPRO Position: Q1 2026 in Review

Point72 Asset Management increased its Spero Therapeutics (SPRO) stake by 37% in Q1 2026, buying an estimated $38.2K and bringing the position to 59,668 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #3577.

Point72 Asset Management first reported a position in SPRO in Q3 2018 and has held it in 3 quarters since. The position peaked at $462K in Q3 2018. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Point72 Asset Management held 59,668 shares of Spero Therapeutics worth $140K as of Q1 2026.
  • Point72 Asset Management bought 16,089 Spero Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Spero Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3577 holding.
  • Point72 Asset Management first reported a position in Spero Therapeutics in Q3 2018 and has held it in 3 quarters since.
  • Point72 Asset Management's Spero Therapeutics position peaked at $462K in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.